Impax Laboratories Inc. v. Lannett Holdings Inc.
1:14-cv-00999
Overview
Parties
Defendant
Lannett Holdings Inc. NPE (Patent Assertion Entity)
Represented By
1 Attorneys ListedFox Rothschild LLP
919 North Market Street, Suite 300, P.O. Box 2323
Lannett Company Inc. Operating Company
Represented By
1 Attorneys ListedFox Rothschild LLP
919 North Market Street, Suite 300, P.O. Box 2323
AstraZeneca AB NPE (Individual / Inventor)
Represented By
3 Attorneys ListedAshby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Impax Laboratories Inc. Operating Company
Represented By
5 Attorneys ListedAshby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Plaintiff
AstraZeneca UK Limited NPE (University / Research)
Represented By
3 Attorneys ListedAshby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | Asserted Patent | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇬🇧 United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| 🌐 PCT International (WIPO) | PCT World Application | View Official Patent → |
Lannett Holdings, Inc. v. AstraZeneca AB
Impax Laboratories Inc. v. Lannett Holdings Inc.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6750237
Pharmaceutical formulations containing zolmitriptan
|
Filed: 2000-11-28
Issued: 2004-06-15
|
Expired (Term Ended)
Expires: 2020-11-28
|
|
|
US7220767
Pharmaceutical formulations containing zolmitriptan
|
Filed: 2004-05-27
Issued: 2007-05-22
|
Expired (Term Ended)
Expires: 2024-05-27
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
6
Dispositive
1
Granted
0
Denied
0
Pending / Review
6
Motions by Category
Key Dispositive Motions & Rulings